Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-03-06 Sale | 2023-03-08 4:29 pm | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 291 | $15.26 | $4,442 | 59,115 (Direct) | View |
| 2023-02-28 Sale | 2023-03-02 7:05 pm | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 1,850 | $15.9 | $29,421 | 38,406 (Direct) | View |
| 2022-03-04 Sale | 2022-03-07 8:49 pm | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 303 | $16.85 | $5,104 | 70,556 (Direct) | View |
| 2022-03-01 Sale | 2022-03-03 4:17 pm | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 420 | $17.75 | $7,456 | 22,259 (Direct) | View |
| 2021-12-27 Sale | 2021-12-28 5:00 pm | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 12,560 | $20.07 | $252,139 | 22,679 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-02-01 Option Award | 2024-02-02 8:27 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 70,000 | $0 | 70,000 (Direct) | View |
| 2023-12-22 Option Award | 2023-12-22 6:00 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 134,953 | $0 | 134,953 (Direct) | View |
| 2023-09-01 Option Award | 2023-09-05 4:10 pm | N/A 2033-09-01 | Aeglea BioTherapeutics Inc. | AGLE | Burrows Scott L Chief Financial Officer | 10,121,441 | $0 | 10,121,441 (Direct) | View |
| 2023-03-02 Option Award | 2023-03-06 6:58 pm | N/A 2033-03-02 | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 76,800 | $0 | 115,206 (Direct) | View |
| 2022-09-16 Exercise | 2022-09-20 4:37 pm | N/A 2029-06-11 | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 5,000 | $0 | 77,533 (Direct) | View |
| 2022-09-16 Exercise | 2022-09-20 4:37 pm | N/A N/A | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 5,000 | $1.6806 | 77,533 (Direct) | View |
| 2022-03-03 Option Award | 2022-03-07 8:49 pm | N/A 2032-03-03 | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 48,600 | $0 | 70,556 (Direct) | View |
| 2021-12-30 Option Award | 2022-01-04 9:05 pm | N/A 2031-08-23 | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 55,704 | $0 | 55,704 (Direct) | View |
| 2021-04-01 Option Award | 2021-04-05 6:50 pm | N/A 2031-04-01 | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 23,000 | $0 | 23,000 (Direct) | View |
Ownership | 2021-04-05 6:49 pm | N/A N/A | Arcutis Biotherapeutics Inc. | ARQT | Burrows Scott L Chief Financial Officer | 0 | $0 | 97,012 (Direct) | View |